News
September 30, 2025
Investor
Notice of the 28th Annual General Meeting of Shareholders 
September 25, 2025
Investor
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
September 24, 2025
Research and Development
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
Investor
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal
September 19, 2025
Investor
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
Investor
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
September 8, 2025
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025
September 8, 2025
Investor
Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary
September 4, 2025
Investor
Notice Regarding Execution of Loan Agreement with Financial Covenants
August 19, 2025
Investor
Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants
September 25, 2025
Investor
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
September 24, 2025
Research and Development
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
Investor
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal
September 19, 2025
Investor
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
Investor
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
September 8, 2025
Investor
Notice Regarding Revision of Full-Year Financial Results Forecast for the Fiscal Year Ended July 2025
September 8, 2025
Investor
Notice Regarding Special Loss (non-consolidated) due to Impairment of Investment in a Subsidiary
September 4, 2025
Investor
Notice Regarding Execution of Loan Agreement with Financial Covenants
August 19, 2025
Investor
Notice Regarding Construction of a New Plant by Our Consolidated Subsidiary and Execution of a Loan Agreement with Financial Covenants